Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials
Top Cited Papers
- 1 December 2008
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Stroke
- Vol. 39 (12) , 3316-3322
- https://doi.org/10.1161/strokeaha.107.510768
Abstract
Background and Purpose— The Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with those seen in randomized, controlled trials (RCTs) when used in routine clinical practice within 3 hours of ischemic stroke onset. We aimed to identify outcome predictors and adjust the outcomes of the SITS-MOST to the baseline characteristics of RCTs. Methods— The study population was SITS-MOST (n=6483) and pooled RCTs (n=464) patients treated with intravenous alteplase within 3 hours of stroke onset. Multivariable, backward stepwise regression analyses (until P≤0.10) were performed to identify the outcome predictors for SITS-MOST. Variables appearing either in the final multivariable model or differing (P<0.10) between SITS-MOST and RCTs were included in the prediction model for the adjustment of outcomes. Main outcome measures were symptomatic intracerebral hemorrhage, defined as Nati...Keywords
This publication has 13 references indexed in Scilit:
- Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational studyThe Lancet, 2007
- The Stroke–Thrombolytic Predictive InstrumentStroke, 2006
- Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?Stroke, 2006
- Sex-Based Differences in the Effect of Intra-Arterial Treatment of StrokeStroke, 2006
- Predictors of major neurologic improvement after thrombolysis in acute strokeNeurology, 2005
- The smoking–thrombolysis paradox and acute ischemic strokeNeurology, 2005
- Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom OnsetJAMA, 1999
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)Published by Elsevier ,1998
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995